Intermittent hypoxia preconditioning can attenuate acute hypoxic injury after a sustained normobaric hypoxic exposure: A randomized clinical trial
CNS Neuroscience & Therapeutics · 2024-03 · 30 (3)
DOI: 10.1111/cns.14662 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 13.03.2024. Verfasst von Yuan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Hypoxia, Altitude Sickness. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, National Basic Research Program of China.
Abstract (Originalsprache)
Background
Intermittent hypoxia (IH) is emerging as a cost‐effective nonpharmacological method for vital organ protection. We aimed to assess the effects of a short‐term moderate intermittent hypoxia preconditioning protocol (four cycles of 13% hypoxia lasting for 10 min with 5‐min normoxia intervals) on acute hypoxic injury induced by sustained hypoxic exposure (oxygen concentration of 11.8% for 6 h).
Methods
One hundred healthy volunteers were recruited and randomized to the IH group and the control group to receive IH or sham‐IH preconditioning for 5 days, respectively, and then were sent to a hypoxic chamber for simulated acute high‐altitude exposure (4500 m).
Results
The overall incidence of acute mountain sickness was 27% (27/100), with 14% (7/50) in the IH group and 40% (20/50) in the control group ( p = 0.003). After 6‐h simulated high‐altitude exposure, the mean Lake Louise Score was lower in the IH group as compared to controls (1.30 ± 1.27 vs. 2.04 ± 1.89, p = 0.024). Mean peripheral oxygen saturations (SpO 2 ) and intracranial pressure (ICP) measures after acute hypoxic exposure exhibited significant differences, with the IH group showing significantly greater SpO 2 values (85.47 ± 5.14 vs. 83.10 ± 5.15%, p = 0.026) and lower ICP levels than the control group (115.59 ± 32.15 vs. 130.36 ± 33.83 mmH 2 O, p = 0.028). IH preconditioning also showed greater effects on serum protein gene product 9.5 (3.89 vs. 29.16 pg/mL; p = 0.048) and C‐reactive protein (−0.28 vs. 0.41 mg/L; p = 0.023).
Conclusion
The short‐term moderate IH improved the tolerance to hypoxia and exerted protection against acute hypoxic injury induced by exposure to sustained normobaric hypoxia, which provided a novel method and randomized controlled trial evidence to develop treatments for hypoxia‐related disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
- Development Coordination Office, Beijing Xiaotangshan Hospital, Beijing, China.
- Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Yuan Wang, Qihan Zhang, Xunming Ji
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- National Basic Research Program of China
Zitieren
APA
Wang, Y., Zhang, Q., Ma, Q., Wang, Q., Huang, D., & Ji, X. (2024). Intermittent hypoxia preconditioning can attenuate acute hypoxic injury after a sustained normobaric hypoxic exposure: A randomized clinical trial. CNS Neuroscience & Therapeutics, 30(3). https://doi.org/10.1111/cns.14662
Vancouver
Wang Y, Zhang Q, Ma Q, Wang Q, Huang D, Ji X. Intermittent hypoxia preconditioning can attenuate acute hypoxic injury after a sustained normobaric hypoxic exposure: A randomized clinical trial. CNS Neuroscience & Therapeutics. 2024;30(3). doi:10.1111/cns.14662
BibTeX
@article{Wang2024,
author = {Wang, Yuan and Zhang, Qihan and Ma, Qingfeng and Wang, Qing and Huang, Dan and Ji, Xunming},
title = {Intermittent hypoxia preconditioning can attenuate acute hypoxic injury after a sustained normobaric hypoxic exposure: A randomized clinical trial},
journal = {CNS Neuroscience & Therapeutics},
year = {2024},
volume = {30},
number = {3},
doi = {10.1111/cns.14662}
}
EUVIMED